A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

Depression Clinical Trial

Official title:

A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00703742
• Other study ID #: Kunming MC
• Status: Completed
• Phase: N/A
• Start date: June 2008
• Est. completion date: June 2011

Study information

• Verified date: September 2019
• Source: Kunming Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is:

1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);

2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).

3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD

4. to find possible predispose to MDD

5. to explore the DNA methylation status in depression;

Description:

1. to explore the pathology of depression

2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease

3. to explore the effect of gene-environment interaction on the epigenetic regulation of the depression

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: June 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• DSM-IV Major Depression or Dysthymia

• Age 18-65

• Physically healthy

• Drug-free

Exclusion Criteria:

• Body metal (e.g., wire stitches, screws in bones, stainless steel hips)

• History of Psychosis or Epilepsy

• Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)

• Bipolar I

• Need for wash-out from effective treatment in order to participate

• Pregnant

• High suicide risk

• Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants

Related Conditions & MeSH terms

• Depression
• Depression Secondary to Other Disease
• Depressive Disorder
• Disease

Intervention

Drug:
• Escitalopram
A,1: Escitalopram, oral, 20 mg/day, 8 weeks

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Kunming Medical College	Kunming	Yunnan

Sponsors (2)

Lead Sponsor	Collaborator
Kunming Medical University	Chinese Academy of Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change of fMRI after medication		baseline, 4 weeks, 8 weeks